Analyst Ratings for [DCPH] Deciphera Pharmaceuticals, Inc.

11/20/23	Resumed	Neutral	X
DCPH Deciphera Pharmaceuticals JP Morgan
$14
10/30/23	Upgrades	Neutral Overweight	X
DCPH Deciphera Pharmaceuticals Piper Sandler
$23
8/10/23	Upgrades	Hold Buy	X
DCPH Deciphera Pharmaceuticals Stifel
$14 $20
1/4/23	Upgrades	Neutral Buy	X
DCPH Deciphera Pharmaceuticals Guggenheim
$22
8/29/22	Initiated	Outperform	X
DCPH Deciphera Pharmaceuticals Cowen
$25
8/5/22	Upgrades	Mkt Perform Mkt Outperform	X
DCPH Deciphera Pharmaceuticals JMP Securities
$23
11/8/21	Downgrades	Overweight Eq Weight	X
DCPH Deciphera Pharmaceuticals Barclays
$50 $11
11/8/21	Downgrades	Buy Hold	X
DCPH Deciphera Pharmaceuticals Canaccord Genuity
$72 $12
11/8/21	Downgrades	Buy Hold	X
DCPH Deciphera Pharmaceuticals Stifel
$60 $10
11/5/21	Downgrades	Buy Hold	X
DCPH Deciphera Pharmaceuticals Truist
$65 $10
3/31/21	Initiated	Outperform	X
DCPH Deciphera Pharmaceuticals Credit Suisse
$78
2/10/21	Upgrades	Mkt Perform Outperform	X
DCPH Deciphera Pharmaceuticals SVB Leerink
$70
7/18/19	Initiated	Buy	X
DCPH Deciphera Pharmaceuticals Deutsche Bank
$42
12/31/18	Upgrades	Neutral Buy	X
DCPH Deciphera Pharmaceuticals B. Riley FBR
$27 $34
9/25/18	Initiated	Underperform	X
DCPH Deciphera Pharmaceuticals Leerink Partners
8/29/18	Initiated	Outperform	X
DCPH Deciphera Pharmaceuticals Raymond James
$47
7/5/18	Initiated	Buy	X
DCPH Deciphera Pharmaceuticals SunTrust
6/19/18	Downgrades	Buy Neutral	X
DCPH Deciphera Pharmaceuticals B. Riley FBR, Inc.
$43
2/16/18	Initiated	Buy	X
DCPH Deciphera Pharmaceuticals B. Riley FBR, Inc.
$43

DCPH Deciphera Pharmaceuticals, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.